Projects per year
Fingerprint
Dive into the research topics where John Park is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
CTU: A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors
Park, J. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff), Chik, J. (Clinical Trial Unit Staff), Delahunt Smoleniec, J. (Clinical Trial Unit Staff) & Gajkowska, A. (Clinical Trial Unit Staff)
11/03/25 → 6/02/26
Project: Research
-
Beamion PANTUMOR-1: CTU: Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours
Park, J. (Primary Chief Investigator), Martin, L. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff), Garcia, M. (Clinical Trial Unit Staff), Quinlan, G. (Clinical Trial Unit Staff), Chapman, N. (Clinical Trial Unit Staff), Armstrong, E. (Clinical Trial Unit Staff) & McHugh, T. (Clinical Trial Unit Staff)
18/09/24 → 12/08/29
Project: Research
-
CTU: First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Park, J. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), Martin, L. (Clinical Trial Unit Staff) & TAIDI, G. (Clinical Trial Unit Staff)
24/05/24 → 30/04/29
Project: Research
-
SGNDV-005: CTU: A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Park, J. (Primary Chief Investigator), Chapman, N. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff) & Martin, L. (Clinical Trial Unit Staff)
1/05/24 → 17/01/29
Project: Research
-
CIBI363A101: CTU: A Phase 1, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas
Park, J. (Primary Chief Investigator), Chester, C. (Clinical Trial Unit Staff), Chapman, N. (Clinical Trial Unit Staff), TAIDI, G. (Clinical Trial Unit Staff) & Martin, L. (Clinical Trial Unit Staff)
12/04/24 → 28/02/29
Project: Research
-
Drug-induced interstitial lung disease in the era of HER2 targeted antibody-drug conjugates: a single centre experience
Zwieky, W., Parsonson, A., Gilchrist, J., Ly, S., Maher, N., Knowles, S., O'Brien, H., Yung, R., Park, J. & Sabanathan, D., Oct 2024, In: Asia-Pacific Journal of Clinical Oncology. 20, Supplement 2, p. 30 1 p.Research output: Contribution to journal › Meeting abstract › peer-review
-
Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy
Smith-Uffen, M., Park, J., Parsonson, A., Kiely, B. E. & Vasista, A., 4 Nov 2024, In: Oncologist. 29, 11, p. 922-930 9 p., oyae089.Research output: Contribution to journal › Review article › peer-review
Open AccessFile22 Downloads (Pure) -
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
McLean, L. S., Lim, A. M., Bressel, M., Lee, J., Ladwa, R., Guminski, A. D., Hughes, B., Bowyer, S., Briscoe, K., Harris, S., Kukard, C., Zielinski, R., Alamgeer, M., Carlino, M., Mo, J., Park, J. J., Khattak, M. A., Day, F. & Rischin, D., 5 Feb 2024, In: Medical Journal of Australia. 220, 2, p. 80-90 11 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Citations (Scopus)37 Downloads (Pure) -
Patterns of toxicity with combined immune checkpoint inhibitors in advanced solid tumours: a single centre experience
Win, S., Parsonson, A. O., Karikios, D., Stevanovic, A., Ding, P., Sabanathan, D. & Park, J. J., Nov 2024, In: Asia-Pacific Journal of Clinical Oncology. 20, Supplement 3, p. 232-233 2 p., 479.Research output: Contribution to journal › Meeting abstract › peer-review
-
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
Park, J. J., Hamad, S. A., Stewart, A., Carlino, M. S., Lim, S. Y. & Rizos, H., 28 Feb 2024, In: Oncogenesis. 13, 1, p. 1-9 9 p., 9.Research output: Contribution to journal › Article › peer-review
Open AccessFile4 Citations (Scopus)72 Downloads (Pure)